AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE
Amgen (NASDAQ:AMGN) has announced a webcasted conference call for the investment community on Tuesday, September 24, 2024, at 1:30 p.m. PT. The call will focus on discussing new topline clinical data from the rocatinlimab (AMG 451/KHK4083) and UPLIZNA® (inebilizumab-cdon) Phase 3 programs.
Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, along with other team members, will participate in the call. The webcast will be accessible to news media, investors, and the general public via Amgen's website at www.amgen.com under the Investors section.
The webcast will be archived and available for replay for at least 90 days after the event. Information about presentation times, webcast availability, and links can be found on Amgen's Investor Relations Events Calendar.
Amgen (NASDAQ:AMGN) ha annunciato una conferenza telefonica in webcast per la comunità d'investimento il martedì 24 settembre 2024, alle 13:30 PT. La chiamata si concentrerà sulla discussione dei nuovi dati clinici preliminari provenienti dai programmi di Fase 3 di rocatinlimab (AMG 451/KHK4083) e UPLIZNA® (inebilizumab-cdon).
Jay Bradner, vicepresidente esecutivo della Ricerca e Sviluppo e chief scientific officer di Amgen, insieme ad altri membri del team, parteciperà alla chiamata. Il webcast sarà accessibile ai media, agli investitori e al pubblico generale tramite il sito web di Amgen all'indirizzo www.amgen.com nella sezione Investitori.
Il webcast sarà archiviato e disponibile per la riproduzione per almeno 90 giorni dopo l'evento. Informazioni sugli orari delle presentazioni, disponibilità del webcast e collegamenti possono essere trovati nel Calendario degli Eventi delle Relazioni con gli Investitori di Amgen.
Amgen (NASDAQ:AMGN) ha anunciado una conferencia telefónica en webcast para la comunidad inversora el martes 24 de septiembre de 2024, a la 1:30 p.m. PT. La llamada se centrará en la discusión de nuevos datos clínicos preliminares de los programas de Fase 3 de rocatinlimab (AMG 451/KHK4083) y UPLIZNA® (inebilizumab-cdon).
Jay Bradner, vicepresidente ejecutivo de Investigación y Desarrollo y director científico de Amgen, junto con otros miembros del equipo, participará en la llamada. El webcast estará accesible para los medios, inversores y el público en general a través del sitio web de Amgen en www.amgen.com en la sección de Inversores.
El webcast se archivará y estará disponible para su reproducción durante al menos 90 días después del evento. La información sobre los horarios de las presentaciones, la disponibilidad del webcast y los enlaces se puede encontrar en el Calendario de Eventos de Relaciones con Inversores de Amgen.
Amgen (NASDAQ:AMGN)은 투자 커뮤니티를 위한 웹캐스트 전화 회의를 2024년 9월 24일 화요일 오후 1시 30분 PT에 개최한다고 발표했습니다. 이 회의는 rocatinlimab (AMG 451/KHK4083) 및 UPLIZNA® (inebilizumab-cdon) 3상 프로그램에서의 새로운 주요 임상 데이터를 논의하는 데 중점을 둘 것입니다.
Jay Bradner는 Amgen의 연구 및 개발 책임 부사장 겸 수석 과학 책임자로, 다른 팀원들과 함께 회의에 참여합니다. 웹캐스트는 Amgen 웹사이트의 www.amgen.com 투자자 섹션을 통해 미디어, 투자자 및 일반 대중이 접근할 수 있습니다.
웹캐스트는 이벤트 이후 최소 90일간 재생 가능하도록 아카이브 됩니다. 발표 시간, 웹캐스트 이용 가능 여부 및 링크에 대한 정보는 Amgen의 투자자 관계 이벤트 캘린더에서 확인할 수 있습니다.
Amgen (NASDAQ:AMGN) a annoncé une conférence téléphonique diffusée en direct pour la communauté d'investissement le mardi 24 septembre 2024 à 13h30 PT. L'appel portera sur la discussion de nouvelles données cliniques préliminaires des programmes de Phase 3 de rocatinlimab (AMG 451/KHK4083) et UPLIZNA® (inebilizumab-cdon).
Jay Bradner, vice-président exécutif de la recherche et du développement et chef des sciences chez Amgen, participera à l'appel avec d'autres membres de l'équipe. Le webcast sera accessible aux médias, aux investisseurs et au grand public via le site web d'Amgen à l'adresse www.amgen.com dans la section Investisseurs.
Le webcast sera archivé et disponible en replay pendant au moins 90 jours après l'événement. Des informations sur les horaires de présentation, la disponibilité du webcast et les liens peuvent être trouvées dans le calendrier des événements des relations investisseurs d'Amgen.
Amgen (NASDAQ:AMGN) hat eine webbasierte Telefonkonferenz für die Investment-Community für Dienstag, den 24. September 2024, um 13:30 Uhr PT angekündigt. Der Fokus der Konferenz wird auf der Diskussion von neuen primären klinischen Daten aus den Phase-3-Programmen von rocatinlimab (AMG 451/KHK4083) und UPLIZNA® (inebilizumab-cdon) liegen.
Jay Bradner, Executive Vice President von Forschung und Entwicklung sowie Chief Scientific Officer von Amgen, wird gemeinsam mit anderen Teammitgliedern an der Konferenz teilnehmen. Der Webcast wird über die Amgen-Website unter www.amgen.com im Bereich Investoren für Medien, Investoren und die breite Öffentlichkeit zugänglich sein.
Der Webcast wird archiviert und mindestens 90 Tage nach der Veranstaltung für eine Wiederholung verfügbar sein. Informationen zu Präsentationszeiten, Verfügbarkeit des Webcasts und Links sind im Eventkalender der Investor Relations von Amgen zu finden.
- None.
- None.
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, TikTok, YouTube and Threads.
CONTACT: Amgen,
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors)
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-host-conference-call-to-discuss-new-topline-data-in-inflammation-and-rare-disease-302256043.html
SOURCE Amgen
FAQ
When is Amgen (AMGN) hosting its conference call to discuss new topline data?
What clinical programs will be discussed during Amgen's (AMGN) upcoming conference call?
Who will be participating in Amgen's (AMGN) September 24, 2024 conference call?
Where can investors access Amgen's (AMGN) September 24, 2024 conference call webcast?
How long will Amgen's (AMGN) September 24, 2024 conference call webcast be available for replay?
